EW vs MDT Stock Comparison: AI Score, Valuation, Performance and Upside
Edwards Lifesciences and Medtronic both compete in the medical device industry, but Edwards Lifesciences concentrates on structural heart disease with a leading transcatheter aortic valve replacement franchise, while Medtronic operates as one of the largest, most diversified medical device makers with businesses spanning cardiac rhythm management, diabetes care, surgical robotics, and neuroscience.
Edwards Lifesciences offers a focused bet on structural heart therapy leadership, while Medtronic offers diversified, large-scale exposure across nearly every major medical device category. Consider whether you prefer Edwards' concentrated growth profile or Medtronic's diversified, scale-driven stability.
EW holds the edge across 4 of 5 key metrics in this comparison. EW has delivered stronger 1-year price return (+10.69% vs +2.08%), though MDT has the better forward P/E setup (14.24x vs 26.71x for EW). EW leads on both revenue growth (13.60%) and operating margin (29.84%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for EW (+11.92%) than for MDT (+8.34%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want concentrated exposure to structural heart disease therapy leadership
- Believe transcatheter aortic valve replacement adoption has continued room to grow globally
- Value deep clinical expertise focused on a specific therapeutic area
- Are comfortable with revenue concentration risk in a single medical device category
- Prefer diversified, large-scale exposure across nearly every major medical device category
- Value an extensive global distribution network and long-standing provider relationships
- Believe surgical robotics and continuous glucose monitoring offer meaningful new growth avenues
- Want a device company less dependent on any single product line's success
| Metric | EW | MDT |
|---|---|---|
| AI scorei | 41.4 | 40.3 |
| AI ranki | #922 | #1037 |
| Latest closei | $89.90 | $94.17 |
| 1M returni | +1.05% | +9.51% |
| 6M returni | +7.16% | +1.25% |
| 1Y returni | +10.69% | +2.08% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EW | MDT |
|---|---|---|
| 1Y ago | $11.1K (+11.0%) started 2025-09-04 | $10.14K (+1.4%) started 2025-09-04 |
| 5Y ago | $7.37K (-26.3%) started 2021-09-07 | $8.89K (-11.1%) started 2021-09-07 |
| 10Y ago | $22.95K (+129.5%) started 2016-09-06 | $17.23K (+72.3%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | EW | MDT |
|---|---|---|
| Market capi | $52B | $116.77B |
| Trailing P/Ei | 53.70 | 24.46 |
| Forward P/Ei | 26.71 | 14.24 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 7.46 | 3.78 |
| Analyst targeti | $100.96 | $98.84 |
| Target upsidei | +11.92% | +8.34% |
| Metric | EW | MDT |
|---|---|---|
| Revenue growthi | 13.60% | 9.90% |
| Earnings growthi | -25.40% | 18.30% |
| EPS growthi | -25.40% | +18.30% |
| FCF margini | +18.92% | +12.72% |
| Operating margini | 29.84% | 22.05% |
| Profit margini | 15.43% | 13.20% |
| ROIC proxyi | 9.18% | 9.84% |
| Return on equityi | 9.18% | 9.84% |
| Dividend yieldi | N/A | 3.16% |
| Betai | 0.85 | 0.57 |
| Debt/equityi | 6.57 | 58.21 |
| Current ratioi | 4.52 | 2.13 |
| Quick ratioi | 3.45 | 1.36 |
Over the past year, EW and MDT have moved weakly in the same direction (correlation of 0.31), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EW | MDT |
|---|---|---|---|
| 1Y | Growthi | +11.04% | +1.42% |
| CAGRi | +11.06% | +1.42% | |
| Volatilityi | 24.49% | 23.36% | |
| Sharpe ratioi | 0.37 | -0.02 | |
| Sortino ratioi | 0.55 | -0.02 | |
| Max drawdowni | 13.19% | 30.00% | |
| Current drawdowni | 5.55% | 10.61% | |
| Avg drawdowni | 4.58% | 12.20% | |
| Ulcer Indexi | 5.65% | 15.14% | |
| Max daily dropi | 3.64% | 5.11% | |
| Max wkly dropi | 7.40% | 7.05% | |
| 5Y | Growthi | -26.31% | -21.38% |
| CAGRi | -5.93% | -4.71% | |
| Volatilityi | 32.71% | 22.45% | |
| Sharpe ratioi | -0.15 | -0.30 | |
| Sortino ratioi | -0.19 | -0.41 | |
| Max drawdowni | 54.32% | 45.10% | |
| Current drawdowni | 31.21% | 21.73% | |
| Avg drawdowni | 34.33% | 28.58% | |
| Ulcer Indexi | 36.37% | 29.69% | |
| Max daily dropi | 31.34% | 7.26% | |
| Max wkly dropi | 30.43% | 11.81% | |
| 10Y | Growthi | +129.45% | +34.73% |
| CAGRi | +8.67% | +3.03% | |
| Volatilityi | 32.23% | 23.53% | |
| Sharpe ratioi | 0.29 | 0.05 | |
| Sortino ratioi | 0.39 | 0.07 | |
| Max drawdowni | 54.32% | 45.10% | |
| Current drawdowni | 31.21% | 21.73% | |
| Avg drawdowni | 20.99% | 17.72% | |
| Ulcer Indexi | 26.79% | 22.03% | |
| Max daily dropi | 31.34% | 12.82% | |
| Max wkly dropi | 30.43% | 19.36% |
| Category | EW | MDT |
|---|---|---|
| Company | Edwards Lifesciences Corporation | Medtronic plc |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A medical technology company focused on structural heart disease and critical care monitoring, best known for pioneering transcatheter aortic valve replacement therapy used to treat heart valve disease without open-heart surgery. | One of the world's largest medical device companies, with a broad portfolio spanning cardiac rhythm management, diabetes care, surgical robotics, and neuroscience devices sold to healthcare providers around the world. |
| Investor focus | Transcatheter aortic valve replacement adoption growth and international expansion, structural heart pipeline progress, and competitive dynamics within the heart valve therapy market. | Growth trends across its cardiac, diabetes, surgical, and neuroscience device segments, new product launches including surgical robotics and continuous glucose monitoring, and international revenue growth. |
- Pioneering position in transcatheter aortic valve replacement therapy established early leadership in a large, growing treatment category
- Focused structural heart portfolio allows deep clinical expertise and sustained research investment in a specific therapeutic area
- Critical care monitoring business provides diversification alongside its core structural heart franchise
- Massive scale and broad product diversification across cardiac, diabetes, surgical, and neuroscience devices provides multiple avenues for growth
- Extensive global distribution network and long-standing healthcare provider relationships support new product adoption worldwide
- Ongoing investment in surgical robotics and continuous glucose monitoring provides exposure to newer, faster-growing device categories
- Faces increasing competition in transcatheter aortic valve replacement from other large medical device manufacturers
- Revenue concentration in structural heart therapies creates exposure to procedure volume and reimbursement changes
- New pipeline therapies must continue to gain regulatory approval and clinical adoption to sustain growth
- Sheer size and portfolio breadth can make it harder to generate the growth rates of more focused, smaller device competitors
- Faces intense competition across nearly every device category it participates in from both large and specialized rivals
- Must continue product innovation to defend share in surgical robotics and continuous glucose monitoring against newer entrants
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.